Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2010

Ingenuity Systems and Sage Couple Respective Software and Predictive Models

  • Ingenuity Systems has given Sage Bionetworks the right to utilize its analysis software, IPA®, and the Ingenuity Knowledge Base of structured biomedical findings to inform and enhance Sage's predictive disease models.

    Sage's web portal will also provide links to the Ingenuity Knowledge Base and IPA. The company's content, algorithms, and predictive disease networks will also be made available within Ingenuity products like IPA.

    Researchers will thus be able to use the content and algorithms from Sage within IPA to analyze molecular data, generate testable hypotheses, and build and visualize predictive disease models. "Leveraging their high-quality, expert-reviewed Ingenuity Knowledge Base Findings and their powerful pathway analytics in our research will enhance and add functionality to our predictive disease networks and algorithms," says Stephen Friend, president, Sage Bionetworks.

    The IPA software helps researchers model, analyze, and understand the complex biological and chemical systems at the core of life science research. It integrates data from a variety of experimental platforms and provides insight into the molecular and chemical interactions, cellular phenotypes, and disease processes of a system.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »